Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spinal Anesthesia for External Cephalic Version
NCT03106753Phase 4Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in breech presentation (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Number of Participants With Success Rate of External Cephalic Version to Cephalic Presentation at Day 1. Started Apr 2017; status: terminated.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
breech presentation
Beyond the preview
Go deeper on NCT03106753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106753.